Plain-English translation of NCT06913647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called canagliflozin can help people with end-stage kidney disease who use peritoneal dialysis (a home-based kidney treatment). The study will look at whether this medication can improve how well the dialysis works and reduce scarring and damage to the membrane used in dialysis.
People on peritoneal dialysis sometimes experience declining treatment effectiveness and scarring of the membrane over time, which can limit how long they can use this dialysis method. Researchers want to see if this medication might help prevent these complications and keep dialysis working better for longer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups: two groups will take the medication or placebo for different periods over 26 weeks, and one group will continue standard care without the new medication. You'll have 4 in-person visits and 1 phone call over 26 weeks, plus 2 safety blood tests. At each in-person visit, you'll have a standard kidney function test called a peritoneal equilibration test (PET).
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada